MX2015011199A - Agentes terapéuticos de csf1. - Google Patents
Agentes terapéuticos de csf1.Info
- Publication number
- MX2015011199A MX2015011199A MX2015011199A MX2015011199A MX2015011199A MX 2015011199 A MX2015011199 A MX 2015011199A MX 2015011199 A MX2015011199 A MX 2015011199A MX 2015011199 A MX2015011199 A MX 2015011199A MX 2015011199 A MX2015011199 A MX 2015011199A
- Authority
- MX
- Mexico
- Prior art keywords
- csf1
- therapeutics
- compositions
- matter
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona composiciones de materia que comprenden una proteína de fusión de CSF-1 y métodos de uso de la misma para mejorar la función de regeneración o restauración de un hígado lesionado. Las composiciones de materia son útiles en el tratamiento de trastornos hepáticos, por ejemplo, en la prevención y/o el tratamiento de enfermedad hepática y para mejorar los resultados tras la cirugía hepática.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201303537A GB201303537D0 (en) | 2013-02-28 | 2013-02-28 | CSF-1 based therapeutics |
GB201320894A GB201320894D0 (en) | 2013-11-27 | 2013-11-27 | CSF-1 Therapeutics |
PCT/GB2014/050595 WO2014132072A1 (en) | 2013-02-28 | 2014-02-28 | Csf1 therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015011199A true MX2015011199A (es) | 2015-12-16 |
Family
ID=50336347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011199A MX2015011199A (es) | 2013-02-28 | 2014-02-28 | Agentes terapéuticos de csf1. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160040142A1 (es) |
EP (1) | EP2961421A1 (es) |
JP (1) | JP2016510977A (es) |
KR (1) | KR20150121715A (es) |
CN (1) | CN105142659A (es) |
AU (1) | AU2014222509A1 (es) |
BR (1) | BR112015020235A2 (es) |
CA (1) | CA2901368A1 (es) |
EA (1) | EA201591501A1 (es) |
MX (1) | MX2015011199A (es) |
WO (1) | WO2014132072A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017176804A1 (en) * | 2016-04-04 | 2017-10-12 | Massachusetts Institute Of Technology | Compositions of crystallized hydrophobic compounds and methods of making and using same |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
GB201906975D0 (en) | 2019-05-17 | 2019-07-03 | Univ Edinburgh | Treatment of ards |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
KR102384683B1 (ko) * | 2020-05-07 | 2022-04-11 | 대한민국 | 구제역 바이러스 억제 활성을 갖는 신규한 돼지 인터페론-알파 융합 단백질 및 이의 용도 |
KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
WO2023246908A1 (zh) * | 2022-06-21 | 2023-12-28 | 四川大学华西医院 | 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
WO1994027435A1 (en) | 1993-06-01 | 1994-12-08 | Life Technologies, Inc. | Genetic immunization with cationic lipids |
AU2003235680A1 (en) * | 2002-01-15 | 2003-07-30 | Duke University | Method of inhibiting atherosclerotic plaque destabilization |
US8652469B2 (en) * | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
JP2010510219A (ja) * | 2006-11-17 | 2010-04-02 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | アミロイド関連障害を処置するためのコロニー刺激因子の全身投与 |
WO2011140249A2 (en) * | 2010-05-04 | 2011-11-10 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
-
2014
- 2014-02-28 CA CA2901368A patent/CA2901368A1/en not_active Abandoned
- 2014-02-28 EP EP14711292.4A patent/EP2961421A1/en not_active Withdrawn
- 2014-02-28 AU AU2014222509A patent/AU2014222509A1/en not_active Abandoned
- 2014-02-28 MX MX2015011199A patent/MX2015011199A/es unknown
- 2014-02-28 JP JP2015559561A patent/JP2016510977A/ja active Pending
- 2014-02-28 BR BR112015020235A patent/BR112015020235A2/pt not_active IP Right Cessation
- 2014-02-28 CN CN201480017323.XA patent/CN105142659A/zh active Pending
- 2014-02-28 US US14/770,767 patent/US20160040142A1/en not_active Abandoned
- 2014-02-28 WO PCT/GB2014/050595 patent/WO2014132072A1/en active Application Filing
- 2014-02-28 KR KR1020157026501A patent/KR20150121715A/ko not_active Application Discontinuation
- 2014-02-28 EA EA201591501A patent/EA201591501A1/ru unknown
-
2017
- 2017-09-08 US US15/699,425 patent/US20180112193A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20150121715A (ko) | 2015-10-29 |
CA2901368A1 (en) | 2014-09-04 |
BR112015020235A2 (pt) | 2017-10-10 |
JP2016510977A (ja) | 2016-04-14 |
AU2014222509A1 (en) | 2015-10-01 |
EP2961421A1 (en) | 2016-01-06 |
US20160040142A1 (en) | 2016-02-11 |
CN105142659A (zh) | 2015-12-09 |
WO2014132072A1 (en) | 2014-09-04 |
US20180112193A1 (en) | 2018-04-26 |
EA201591501A1 (ru) | 2016-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011199A (es) | Agentes terapéuticos de csf1. | |
PH12015502087A1 (en) | Newcastle disease viruses and uses thereof | |
MY195289A (en) | Anti IL-36R Antibodies | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
MX361349B (es) | Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas. | |
MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
PH12015502829A1 (en) | Lectin-like oxidized ldl receptor1 antibodies and methods of use | |
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
PH12017500304A1 (en) | Vaccine compositions against dengue virus diseases | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
BR112015016033A2 (pt) | composições e métodos para tratamento de infecções por bactérias | |
MX345534B (es) | Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas. | |
MX2016005473A (es) | Metodos y composiciones para mejorar la funcion renal. | |
MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
WO2013163562A3 (en) | Compositions and methods for treating ptsd and related diseases | |
MX2018004532A (es) | Combinacion de trazodona y gabapentina para el tratamiento de dolor. | |
WO2015003049A3 (en) | Compositions and methods to treat inflammatory joint disease | |
IN2013MU03429A (es) | ||
BR112016029044A2 (pt) | ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite |